The Latest Cardiac and Vascular News
Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) Silence to host R&D Day in New York City on October 21, 2021 August 12, 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery […]
Entered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment milestone with first 143 bentracimab patients enrolled in the REVERSE-IT pivotal Phase 3 trial, with top-line […]
Phase 2/3 ReMEDy2 Trial in AIS for Stroke Outcomes and Stroke Recurrence on Track for Initiation Summer 2021 Positive REDUX Phase 2 Interim Data Announced for CKD: IgA Nephropathy Data Indicate Statistically & Clinically Significant 33% Reduction in Albuminuria (UACR). Board of Directors Strengthened with Election of Two Pharma Industry […]
FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept. 6, 2021. DelOrefice succeeds Christopher Reidy, 64, who announced his intent to retire from BD last week. DelOrefice, 50, […]
U.S. venture capital firms, METIS Innovative and ShangBay Capital, co-lead funding round and join board to accelerate company growth and development of unique bioabsorbable stent to cure brain aneurysms CALGARY, AB, Aug. 11, 2021 /PRNewswire/ – Fluid Biotech Inc., a medical device start-up company in Calgary, Alberta, Canada, today announced the completion of […]
VANCOUVER and MINNEAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today reported financial results for the second quarter ended June 30, 2021. Second Quarter Highlights Generated revenue of approximately $633,000 in the quarter, up 123% from the same period in 2020, and a sequential […]
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4 Announced positive top-line results from the FREEDOM-HF study demonstrating that average 30-day heart failure-related costs were […]
IRVINE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021. Second Quarter Revenue […]
– Revenues Increased 41% Year-over-Year to $12.6 Million – – U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million – – Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT […]
– Company established with world-class research from leading academia and industry leaders– Lead program targets a novel kinase involved in cellular stress response – Experienced and proven team advancing therapies for Long QT Syndrome and resistant cancers LAVAL, QC, Aug. 10, 2021 /PRNewswire/ – LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the […]
